Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Investing Articles

    One Reason Why I Would Buy AstraZeneca plc Today

    | Royston Wild

    Royston Wild explains why AstraZeneca plc (LON: AZN) could become a high-profile acquisition target once again.

    Read more »

    Investing Articles

    How Strong Are AstraZeneca plc’s Dividends?

    | Alan Oscroft

    AstraZeneca plc (LON:AZN) can afford to keep handing out the cash for a couple more years or so.

    Read more »

    Investing Articles

    AstraZeneca plc And Shire PLC Bolster Takeover Defences

    | Rupert Hargreaves

    Shire PLC (LON: SHP) and AstraZeneca plc (LON: AZN) are working to repel hostile buyers.

    Read more »

    Investing Articles

    One Reason Why I Wouldn’t Buy AstraZeneca plc Today

    | Royston Wild

    Royston Wild explains why AstraZeneca plc (LON: AZN) is a poor growth selection.

    Read more »

    Investing Articles

    Neil Woodford’s First Buys For His New Fund

    | G A Chester

    Disclosures by RM2 International SA (LON:RM2), ReNeuron Group Plc (LON:RENE), e-Therapeutics plc (LON:ETX); speculation on AstraZeneca plc (LON:AZN) and BAE…

    Read more »

    Investing Articles

    Why Shire PLC’s Takeover Response Is Highly Unusual

    | Peter Stephens

    After Abbvie’s £27bn takeover offer was rejected, Shire PLC (LON: SHP) has responded in a rather unusual way...

    Read more »

    Company Comment

    Look No Further Than AstraZeneca plc For Growth And Income

    | Mark Stones

    AstraZeneca plc's (LON: AZN) impressive drugs pipeline and ambitious revenue targets make it my preferred pharma stock.

    Read more »

    Investing Articles

    Why Is AstraZenenca plc So Expensive?

    | Alan Oscroft

    Why AstraZenenca plc (LON: AZN) shares are looking pricey.

    Read more »

    Investing Articles

    AstraZeneca plc’s Not So Secret Weapon

    | Rupert Hargreaves

    AstraZeneca plc's (LON: AZN) CEO is committed to the company.

    Read more »

    Investing Articles

    This Thing Could Put A Rocket Under AstraZeneca plc’s Shares

    | G A Chester

    AstraZeneca plc (LON:AZN) has 35% potential upside.

    Read more »

    Investing Articles

    A New Bid For AstraZeneca plc In November?

    | Alan Oscroft

    Pfizer may be back for another tilt at AstraZenenca plc (LON: AZN).

    Read more »

    Investing Articles

    Should I Invest In AstraZeneca Plc Now?

    | Kevin Godbold

    Can AstraZeneca plc (LON: AZN) still deliver a decent investment return?

    Read more »